Kim Drapkin

🌟 Nykode's Brian Weinert is participating in the Nature Conferences: Cancer Immunotherapy meeting in Boston, MA, from June 10th through June 12th. Our team is presenting research on our innovative cancer vaccine technology, which incorporates advanced mRNA-lipid nanoparticle (LNP) formats.   🔍 Our study, featured in poster presentation # 2-22 on June 11th, compares an APC-targeted neoantigen mRNA vaccine to an untargeted version across various mRNA-LNP doses. The APC-targeted vaccine consistently induced a stronger and broader immune response. In a mouse model of colorectal cancer, it also demonstrated superior tumor control and significantly better survival outcomes than the untargeted mRNA vaccine.   📊 For more details, please visit our poster on our website: https://lnkd.in/eh4Nrx76   #CancerResearch #Immunotherapy #Biotechnology #NatureConf #NatureCancer #NatureMedicine #NatImmunol   https://lnkd.in/eFMJeAJW

98

Since 2015, Dana-Farber researchers have been participating in clinical trials that evaluate the use of bispecific antibodies for patients with non-Hodgkin lymphoma. Three bispecific antibody therapies have been FDA approved with more on the horizon. These are exciting new medicines that rally the immune system in a powerful way to fight blood cancers. But rolling out a new type of medicine is a project of its own. The experts at Dana-Farber who have been treating patients with these new medicines are now working on expanding their use. Philippe Armand, MD, PhD, chief of the Lymphoma Program, and Jennifer Crombie, MD, Reid Merryman, MD, and Christine Ryan, MD, physicians and clinical investigators in the Lymphoma Program, are using what they have learned as clinical investigators to run new trials to determine if these medicines could have benefits earlier in treatment, in combination with other therapies, or in other types of lymphoma. “The hope is that these drugs will help improve outcomes for patients with lymphoma,” says Crombie, who has been the principal investigator of a bispecific antibody trial for the past few years. Monoclonal antibodies treat cancer by binding to markers on cancer cells and rallying the immune system to destroy them. Bispecific antibodies are designed to recognize and bind to more than one cell marker. The bispecific antibodies approved for the treatment of B-cell non-Hodgkin lymphoma recognize CD20, a marker known to be on B cells, and CD3, a marker known to be on T cells, which are immune cells that can attack cancer cells. By binding to both, the bispecific antibody pulls the T cells closer to the cancerous B cells, increasing the chances that the T cells will recognize and kill the cancer. “Bispecific antibodies can be a powerful immune-based mechanism because of their dual binding properties,” says Crombie. These medicines are currently approved for use alone in patients with follicular lymphoma or diffuse large-cell lymphoma who have received three lines of treatment and need a new therapeutic option. Some patients may choose to try bispecific antibody therapy after CAR T-cell therapy. Others may opt to try bispecific antibodies before trying, or in lieu of, CAR T-cell therapy. Recommendations will vary depending on the type of lymphoma and other individual factors. These new therapies are administered via infusion or an injection under the skin. However, these immunotherapies can cause side effects that many centers are learning how best to manage. In clinical trials of bispecific antibodies, investigators noted side effects that are like those experienced by patients receiving CAR T-cell therapy. The reactions, however, are often less frequent and less severe. Learn more: https://lnkd.in/e4D8T2GG

160

We look forward to hearing Christine Rothe, CDO of iOmx, speak at the 6th Annual Macrophage-Directed Therapies Summit in Boston on October 2nd. Christine will provide key insights into IOMX-0675, our highly differentiated, fully human, cross-specific antibody targeting LILRB1 and LILRB2. In the presentation, Christine will discuss how IOMX-0675 effectively repolarizes the tumor microenvironment, resulting in potent tumor cell killing both 𝘪𝘯 𝘷𝘪𝘵𝘳𝘰 and 𝘪𝘯 𝘷𝘪𝘷𝘰. Also, Christine will highlight IOMX-0675's unique binding profile, which selectively antagonizes the immunosuppressive receptors LILRB1 and LILRB2 while sparing the immuno-activating family members. This differentiation results in superior macrophage repolarization and immune cell activation compared to other antibodies. 🔬   📢 Stay tuned for further updates!   Hanson Wade Group #CancerResearch #Macrophages #immunotherapy #ImmunoOncology

70